Closed Loop Medicine (CLM) has appointed Kate Woolland as Chief Executive Officer. Previously serving as Chief Operating Officer, she will lead the company into a new phase focused on scaling its innovation platform through strategic partnerships and commercialisation of its intellectual property.
CLM has built a global IP portfolio with more than 60 filings across 16 patent families, covering platform and therapy-specific dosing technologies, including GLP-1 therapies and hypertension.
With clearances in the UK and US and ISO13485/ISO27001 certification, the company is well-positioned for expansion in the growing metabolic health sector. Its titration-based approach has demonstrated improved adherence above 90% in clinical settings.
Kate said: “Our precision dosing platform has reached a maturity that creates strategic value for pharmaceutical and health delivery partners. As we enter this new phase, we’re focused on partnering with organisations that can leverage our technology at scale across multiple therapeutic areas.”
She brings deep commercial and operational experience to the role, having previously launched healthcare products at ieso Digital Health and built a multimillion-pound health transformation practice at PA Consulting.
Her focus will be on maximising the value of CLM’s platform through pharmaceutical partnerships, life cycle management and digital health integration, while also supporting differentiated generics.
Chair of the Board, Luba Greenwood, noted: “Kate’s appointment is well timed as we transition from product development to value realisation. Her commercial insight and strategic focus are exactly what’s needed for this next phase.”
